HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study

Background/Aims Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus. The purpose of this assessment wa...

Cijeli opis

Bibliografski detalji

Glavni autori:	Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, Ru Bai, Junwei Cheng, Meng Yu, Alexander Liberman, Liping Liu, Nadege Gunn
Format:	Artigo
Jezik:	Inglês
Izdano:	Korean Association for the Study of the Liver 2025-07-01
Serija:	Clinical and Molecular Hepatology
Teme:	noninvasive biomarkers liver histology metabolic dysfunction-associated steatohepatitis
Online pristup:	http://e-cmh.org/upload/pdf/cmh-2025-0145.pdf
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!